Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

Listen to Noopur Raje, MD, answer audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.
Noopur Raje, MD
Released: March 12, 2021

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:

  • Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?
  • Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?
  • What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?
  • What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?

Presenter:

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Acknowledgements

Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Related Content

Download these expert-selected slides from Clinical Care Options (CCO) on acute myeloid leukemia to help provide optimal treatment for your patients with AML.

Amir T. Fathi, MD Eunice S. Wang, MD Released: October 21, 2021

Shaji Kumar, MD, and Beth Faiman, PhD, share expert guidance on diagnosing and managing patients with AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 21, 2021 Expired: October 20, 2022

Downloadable slideset on diagnosing and managing AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Released: October 21, 2021

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue